Shares Magazine
5.72p+0.06 (+0.99%)05 Jul 2022, 11:29
Jump to:
Immupharma PLC Fundamentals
| Company Name | Immupharma PLC | Last Updated | 2022-07-05 |
|---|---|---|---|
| Industry | Biotechnology | Sector | Healthcare |
| Shares in Issue | 284.985 m | Market Cap | £16.29 m |
| PE Ratio | 0.00 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£0.03 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.0001 | Debt Equity Ratio | 0 |
| Asset Equity Ratio | 1.3590 | Cash Equity Ratio | 0.3624 |
| Quick Ratio | 1.2451 | Current Ratio | 2.11 |
| Price To Book Value | 3.6550 | ROCE | 0 |
Immupharma PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Immupharma PLC Company Financials
| Assets | 2021 | 2020 | 2019 |
|---|---|---|---|
| Tangible Assets | £352,996.00 | £411,606.00 | £206,744.00 |
| Intangible Assets | £477,553.00 | £484,042.00 | £478,959.00 |
| Investments | £1.42 m | £2.42 m | £690,910.00 |
| Total Fixed Assets | £2.65 m | £3.49 m | £2.22 m |
| Stocks | 0 | 0 | 0 |
| Debtors | £373,253.00 | £95,339.00 | £102,924.00 |
| Cash & Equivalents | £1.60 m | £5.86 m | £1.36 m |
| Other Assets | £405,489.00 | £174,488.00 | £843,148.00 |
| Total Assets | £6.00 m | £10.92 m | £5.80 m |
| Liabilities | 2021 | 2020 | 2019 |
|---|---|---|---|
| Creditors within 1 year | £1.58 m | £1.26 m | £531,867.00 |
| Creditors after 1 year | 0 | 0 | 0 |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £1.58 m | £1.26 m | £531,867.00 |
| Net assets | £4.41 m | £9.65 m | £5.27 m |
| Equity | 2021 | 2020 | 2019 |
|---|---|---|---|
| Called up share capital | £28.50 m | £25.02 m | £16.74 m |
| Share Premium | £27.24 m | £27.24 m | £27.19 m |
| Profit / Loss | -£8.94 m | -£7.25 m | -£6.74 m |
| Other Equity | £4.41 m | £9.65 m | £5.27 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | £4.41 m | £9.65 m | £5.27 m |
| Ratios | 2021 | 2020 | 2019 |
|---|---|---|---|
| Debt Ratio | 0 | 0 | 0 |
| Debt-to-Equity | 0 | 0 | 0 |
| Assets / Equity | 1.3590 | 1.3590 | 1.3590 |
| Cash / Equity | 0.3624 | 0.3624 | 0.3624 |
| EPS | -£0.02 | -£0.03 | -£0.04 |
| Cash Flow | 2021 | 2020 | 2019 |
|---|---|---|---|
| Cash from operating activities | -£4.83 m | -£3.33 m | -£4.22 m |
| Cashflow before financing | -£4.13 m | £5.04 m | -£3.90 m |
| Increase in Cash | -£4.18 m | £4.47 m | -£4.00 m |
| Income | 2021 | 2020 | 2019 |
|---|---|---|---|
| Turnover | £118,350.00 | £126,667.00 | £77,925.00 |
| Cost of sales | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Operating Profit | -£6.59 m | -£5.59 m | -£6.28 m |
| Pre-Tax profit | -£8.94 m | -£7.25 m | -£6.74 m |
Immupharma PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | ImmuPharma PLC is a drug discovery and development company. Its pipeline includes novel peptide-based therapeutics within four therapy areas: Autoimmunity & Inflammation, Anti-Infectives, Metabolism, and Cancer. Its lead drug candidate is Lupuzor, which is a treatment for lupus and life-threatening autoimmune disease. |
| Latest Interim Date | 29 Sep 2021 |
| Latest Fiscal Year End Date | 25 May 2022 |
Immupharma PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2021-07-30 | Dr. Franco Di Muzio | Non-Executive Director |
| 2006-03-31 | Mr. Douglas Gordon James Paterson | Non-Executive Director |
| 2022-06-01 | Mr. Timothy Paul McCarthy | Executive Director,Chairman and Chief Executive Officer |
| 2021-07-30 | Mr. Dimitri Dimitriou | Executive Director,Chief Executive Officer |
| 2021-05-24 | Dr. Robert Henri Zimmer | Executive Director,President and Chief Scientific Officer |
| 2016-05-05 | Mr. Richard Leonard Warr | Executive Director,Chairman |
| 2016-05-05 | Dr. Ajay Agrawal | Non-Executive Director |
| 2011-08-09 | Mr. Paddy Hugh Walker-Taylor FCA,MCT | Executive Director,Chief Financial Officer |
| 2006-03-31 | Mr. Anthony Johnson B.Pharm,MSc | Non-Executive Director |
| 2021-08-24 | Dr. Sanjeev Pandya | Non-Executive Director,Senior Independent Director |
| 2021-07-30 | Dr. Stephane Robert George Mery | Non-Executive Director |
| 2022-06-01 | Mr. Timothy Gary Franklin | Executive Director,Chief Operating Officer |
| 2022-06-01 | Ms. Lisa Baderoon | Non-Executive Director |
Immupharma PLC Contact Details
| Company Name | ImmuPharma PLC |
|---|---|
| Address | One Bartholomew Close, London, EC1A 7BL |
| Telephone | +44 2071524080 |
| Website | http://www.immupharma.com |
Immupharma PLC Advisors
| Stockbroker | Bryan, Garnier & Co Limited |
|---|---|
| Phone | +44 2073322500 |
| Nominated Adviser | Northland Capital Partners |
|---|---|
| Phone | +44 2038616625 |
| Fax | +44 2076005975 |
| Stockbroker | Northland Capital Partners |
|---|---|
| Phone | +44 2038616625 |
| Fax | +44 2076005975 |
| Registrar | Computershare Investor Services PLC |
|---|---|
| Phone | +44 3707020003 |
| Fax | +44 3707036101 |
| Auditor | Nexia Smith & Williamson |
|---|---|
| Phone | +44 2071314000 |
| Fax | +44 2071314001 |
| Solicitor | Bircham Dyson Bell |
|---|---|
| Phone | +44 2072277000 |
| Fax | +44 2072223480 |
| Bank | Royal Bank of Scotland PLC |
|---|
| Auditor | Nexia Smith & Williamson Audit Limited |
|---|
Sign up to our
daily email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Dechra Pharmaceuticals PLC | 3,620.00 | 5.42 |
| Moneysupermarket.Com Group PLC | 183.20 | 4.21 |
| Synthomer PLC | 229.50 | 3.19 |
| Ascential PLC | 270.00 | 2.97 |
| Croda International PLC | 6,732.00 | 2.37 |
| Segro PLC | 970.20 | 2.06 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Rolls-Royce Holdings PLC | 82.28 | -4.92 |
| Anglo American PLC | 2,702.00 | -4.86 |
| Antofagasta PLC | 1,054.00 | -4.79 |
| Wpp PLC | 767.60 | -4.67 |
| Just Group PLC | 65.90 | -4.97 |
| Dunelm Group PLC | 783.00 | -4.34 |
